as well as multiple doses in obese patients with or without type 2 diabetes in combination with incretin therapy.” In September, the company sought approval to conduct a Phase I/IIa trial in New ...

Since its discovery, RNA interference (RNAi ... due to an increase in energy expenditure—a distinct mechanism from incretin-based anti-obesity drugs like semaglutide,” explained Dong Ki ...